Physician profile
Danielle E Barclay
NPI 1366955015
$832.13
in general payments reported to CMS, 2019-2025
14 companies · $670 in 2025
The $670 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $162 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $178.87 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $153.82 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $92.39 | 2025 | Airsupra, Breztri |
| Abbvie INC. | $71.39 | 2025 | |
| Lilly USA, LLC | $58.42 | 2024-2025 | Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $50.57 | 2025 | Voquezna |
| Pfizer INC. | $41.70 | 2024-2025 | |
| Dexcom, INC. | $37.55 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.00 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $26.51 | 2024 | Auvelity |
| Verona Pharma, INC. | $24.46 | 2025 | Ohtuvayre |
| Acadia Pharmaceuticals INC | $23.95 | 2025 | Daybue |
| Glaxosmithkline, LLC. | $19.62 | 2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $16.88 | 2025 | Gardasil 9, Vaxelis, Rotateq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Barclay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.